Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.38 +5.3%	$1.83	$1.11 ▼ $5.00	$633.41M	1.81	1.59 million shs	996,629 shs
COYA Coya Therapeutics	$6.00 +2.2%	$5.83	$4.65 ▼ $10.24	$100.35M	0.26	72,319 shs	41,256 shs
RLAY Relay Therapeutics	$3.57 +0.6%	$3.19	$1.78 ▼ $10.72	$612.08M	1.62	2.07 million shs	548,829 shs
SNDL SNDL	$1.37 +10.1%	$1.30	$1.15 ▼ $2.40	$358.70M	3.4	1.96 million shs	3.36 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	-4.64%	-0.88%	-3.42%	+91.53%	-34.49%
COYA Coya Therapeutics	-6.30%	+2.09%	-0.17%	+17.87%	-9.69%
RLAY Relay Therapeutics	-1.93%	+2.60%	+5.65%	+77.50%	-44.18%
SNDL SNDL	-2.75%	+2.48%	-6.06%	-2.36%	-36.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.1323 of 5 stars	3.5	1.0	0.6	3.3	0.6
COYA Coya Therapeutics	2.3031 of 5 stars	3.5	4.0	1.9	0.8	0.0
RLAY Relay Therapeutics	2.8063 of 5 stars	3.4	2.0	2.8	2.5	0.6
SNDL SNDL	3.6623 of 5 stars	3.5	5.0	2.1	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.32	291.60% Upside
COYA Coya Therapeutics	3.00	Buy	$16.67	177.78% Upside
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	394.86% Upside
SNDL SNDL	3.00	Buy	$3.63	165.57% Upside

Current Analyst Ratings Breakdown

Latest COYA, SNDL, AUTL, and RLAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/9/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00
4/28/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/17/2025	RLAY Relay Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$4.00
4/10/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.12M	62.59	N/A	N/A	$1.61 per share	1.48
COYA Coya Therapeutics	$3.69M	27.23	N/A	N/A	$2.37 per share	2.53
RLAY Relay Therapeutics	$10.01M	61.15	N/A	N/A	$4.65 per share	0.77
SNDL SNDL	$671.81M	0.53	N/A	N/A	$3.15 per share	0.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/8/2025 (Estimated)
COYA Coya Therapeutics	-$14.88M	-$1.07	N/A	N/A	N/A	N/A	-48.88%	-43.32%	8/11/2025 (Estimated)
RLAY Relay Therapeutics	-$337.71M	-$2.23	N/A	N/A	N/A	N/A	-44.17%	-39.53%	8/5/2025 (Estimated)
SNDL SNDL	-$69.18M	-$0.29	N/A	N/A	N/A	-11.48%	-9.02%	-7.60%	7/30/2025 (Estimated)

Latest COYA, SNDL, AUTL, and RLAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	RLAY Relay Therapeutics	-$0.49	N/A	N/A	N/A	$0.07 million	N/A
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million
5/1/2025	Q1 2025	SNDL SNDL	-$0.06	-$0.04	+$0.02	-$0.04	$214.60 million	$142.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDL SNDL	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	9.24	9.02
COYA Coya Therapeutics	N/A	8.84	8.84
RLAY Relay Therapeutics	N/A	19.96	19.96
SNDL SNDL	0.10	4.62	3.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
COYA Coya Therapeutics	39.75%
RLAY Relay Therapeutics	96.98%
SNDL SNDL	N/A

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
COYA Coya Therapeutics	12.00%
RLAY Relay Therapeutics	4.32%
SNDL SNDL	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
RLAY Relay Therapeutics	330	171.45 million	164.04 million	Optionable
SNDL SNDL	2,516	262.78 million	N/A	Optionable

COYA, SNDL, AUTL, and RLAY Headlines

Recent News About These Companies

Sundial Raises $23M to Redefine Data-informed Decisions with AI

July 8 at 10:27 AM | businesswire.com

3 Marijuana Stocks For The Investor To Consider Before A Recovery

July 7 at 9:21 AM | marijuanastocks.comM

SNDL (NASDAQ:SNDL) Trading 2% Higher - Here's What Happened

July 4, 2025 | marketbeat.com

SNDL Inc. Announces Virtual Annual and Special Shareholders Meeting for July 2025

June 20, 2025 | tipranks.com

3 Cannabis Stocks For Investors To Secure For Future Gains

June 20, 2025 | marijuanastocks.comM

1CM Receives Court Approval for Arrangement with SNDL Inc

June 18, 2025 | newsfilecorp.comN

1CM Inc. Gains Court Approval for SNDL Arrangement

June 18, 2025 | tipranks.com

HYTN Receives Initial International Purchase Order for GMP Vape Cartridges

June 11, 2025 | finance.yahoo.com

Marijuana Stocks To Watch With Strong Market Potential

June 6, 2025 | marijuanastocks.comM

1CM Mails Circular for Annual and Special Meeting of Shareholders and Announces Receipt of Interim Court Order

May 20, 2025 | finance.yahoo.com

Canadian Securities Exchange Reports April 2025 Performance Figures

May 15, 2025 | finance.yahoo.com

SA analyst downgrades: KO, SNDL, MKL, KTOS, CAKE, CBRE, OLLI

May 5, 2025 | msn.com

SNDL Inc. Reports Record Profit Margins For Q1 2025, But Investor Risk Has Increased

May 5, 2025 | seekingalpha.com

SNDL Inc. (NASDAQ:SNDL) Q1 2025 Earnings Call Transcript

May 3, 2025 | insidermonkey.com

SNDL First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

May 3, 2025 | finance.yahoo.com

3 Marijuana Stocks For The Long Term Investing

May 2, 2025 | marijuanastocks.comM

SNDL Inc (SNDL) Q1 2025 Earnings Call Highlights: Record Gross Margin and Strategic US Market Review

May 2, 2025 | uk.finance.yahoo.com

These Cannabis Companies Are Repurchasing Shares

May 2, 2025 | newcannabisventures.comN

SNDL Inc. (SNDL) Q1 2025 Earnings Call Transcript

May 2, 2025 | seekingalpha.com

SNDL 1Q Loss Widens

May 2, 2025 | marketwatch.com

SNDL Inc. Earnings Call Highlights Growth and Challenges

May 1, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, SNDL, AUTL, and RLAY Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.38 +0.12 (+5.31%)

As of 03:01 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Coya Therapeutics NASDAQ:COYA

$6.00 +0.13 (+2.21%)

As of 03:06 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Relay Therapeutics NASDAQ:RLAY

$3.57 +0.02 (+0.56%)

As of 03:10 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

SNDL NASDAQ:SNDL

$1.36 +0.13 (+10.08%)

As of 03:09 PM Eastern

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time